Literature DB >> 21700325

Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathies.

Joseph R Mazzulli1, You-Hai Xu, Ying Sun, Adam L Knight, Pamela J McLean, Guy A Caldwell, Ellen Sidransky, Gregory A Grabowski, Dimitri Krainc.   

Abstract

Parkinson's disease (PD), an adult neurodegenerative disorder, has been clinically linked to the lysosomal storage disorder Gaucher disease (GD), but the mechanistic connection is not known. Here, we show that functional loss of GD-linked glucocerebrosidase (GCase) in primary cultures or human iPS neurons compromises lysosomal protein degradation, causes accumulation of α-synuclein (α-syn), and results in neurotoxicity through aggregation-dependent mechanisms. Glucosylceramide (GlcCer), the GCase substrate, directly influenced amyloid formation of purified α-syn by stabilizing soluble oligomeric intermediates. We further demonstrate that α-syn inhibits the lysosomal activity of normal GCase in neurons and idiopathic PD brain, suggesting that GCase depletion contributes to the pathogenesis of sporadic synucleinopathies. These findings suggest that the bidirectional effect of α-syn and GCase forms a positive feedback loop that may lead to a self-propagating disease. Therefore, improved targeting of GCase to lysosomes may represent a specific therapeutic approach for PD and other synucleinopathies.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21700325      PMCID: PMC3132082          DOI: 10.1016/j.cell.2011.06.001

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  38 in total

1.  Phenotype, diagnosis, and treatment of Gaucher's disease.

Authors:  Gregory A Grabowski
Journal:  Lancet       Date:  2008-10-04       Impact factor: 79.321

2.  Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease.

Authors:  E Sidransky; M A Nalls; J O Aasly; J Aharon-Peretz; G Annesi; E R Barbosa; A Bar-Shira; D Berg; J Bras; A Brice; C-M Chen; L N Clark; C Condroyer; E V De Marco; A Dürr; M J Eblan; S Fahn; M J Farrer; H-C Fung; Z Gan-Or; T Gasser; R Gershoni-Baruch; N Giladi; A Griffith; T Gurevich; C Januario; P Kropp; A E Lang; G-J Lee-Chen; S Lesage; K Marder; I F Mata; A Mirelman; J Mitsui; I Mizuta; G Nicoletti; C Oliveira; R Ottman; A Orr-Urtreger; L V Pereira; A Quattrone; E Rogaeva; A Rolfs; H Rosenbaum; R Rozenberg; A Samii; T Samaddar; C Schulte; M Sharma; A Singleton; M Spitz; E-K Tan; N Tayebi; T Toda; A R Troiano; S Tsuji; M Wittstock; T G Wolfsberg; Y-R Wu; C P Zabetian; Y Zhao; S G Ziegler
Journal:  N Engl J Med       Date:  2009-10-22       Impact factor: 91.245

3.  The risk of Parkinson's disease in type 1 Gaucher disease.

Authors:  Gilberto Bultron; Katherine Kacena; Daniel Pearson; Michael Boxer; Ruhua Yang; Swati Sathe; Gregory Pastores; Pramod K Mistry
Journal:  J Inherit Metab Dis       Date:  2010-02-23       Impact factor: 4.982

4.  Distinct region-specific alpha-synuclein oligomers in A53T transgenic mice: implications for neurodegeneration.

Authors:  Elpida Tsika; Maria Moysidou; Jing Guo; Mimi Cushman; Patrick Gannon; Raphael Sandaltzopoulos; Benoit I Giasson; Dimitri Krainc; Harry Ischiropoulos; Joseph R Mazzulli
Journal:  J Neurosci       Date:  2010-03-03       Impact factor: 6.167

5.  Accumulation and distribution of α-synuclein and ubiquitin in the CNS of Gaucher disease mouse models.

Authors:  Y H Xu; Y Sun; H Ran; B Quinn; D Witte; G A Grabowski
Journal:  Mol Genet Metab       Date:  2010-12-31       Impact factor: 4.797

6.  Mitochondrial Parkin recruitment is impaired in neurons derived from mutant PINK1 induced pluripotent stem cells.

Authors:  Philip Seibler; John Graziotto; Hyun Jeong; Filip Simunovic; Christine Klein; Dimitri Krainc
Journal:  J Neurosci       Date:  2011-04-20       Impact factor: 6.167

7.  Alpha-synuclein delays endoplasmic reticulum (ER)-to-Golgi transport in mammalian cells by antagonizing ER/Golgi SNAREs.

Authors:  Nandhakumar Thayanidhi; Jared R Helm; Deborah C Nycz; Marvin Bentley; Yingjian Liang; Jesse C Hay
Journal:  Mol Biol Cell       Date:  2010-04-14       Impact factor: 4.138

8.  Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease.

Authors:  Juliane Neumann; Jose Bras; Emma Deas; Sean S O'Sullivan; Laura Parkkinen; Robin H Lachmann; Abi Li; Janice Holton; Rita Guerreiro; Reema Paudel; Badmavady Segarane; Andrew Singleton; Andrew Lees; John Hardy; Henry Houlden; Tamas Revesz; Nicholas W Wood
Journal:  Brain       Date:  2009-03-13       Impact factor: 13.501

9.  Alpha-synuclein-glucocerebrosidase interactions in pharmacological Gaucher models: a biological link between Gaucher disease and parkinsonism.

Authors:  Amy B Manning-Boğ; Birgitt Schüle; J William Langston
Journal:  Neurotoxicology       Date:  2009-07-02       Impact factor: 4.294

10.  Cellular oligomerization of alpha-synuclein is determined by the interaction of oxidized catechols with a C-terminal sequence.

Authors:  Joseph R Mazzulli; Maria Armakola; Michelle Dumoulin; Ioannis Parastatidis; Harry Ischiropoulos
Journal:  J Biol Chem       Date:  2007-09-04       Impact factor: 5.157

View more
  541 in total

Review 1.  Parkinson's disease pathogenesis from the viewpoint of small fish models.

Authors:  Hideaki Matsui; Ryosuke Takahashi
Journal:  J Neural Transm (Vienna)       Date:  2017-08-02       Impact factor: 3.575

2.  Autoproteolytic fragments are intermediates in the oligomerization/aggregation of the Parkinson's disease protein alpha-synuclein as revealed by ion mobility mass spectrometry.

Authors:  Camelia Vlad; Kathrin Lindner; Christiaan Karreman; Stefan Schildknecht; Marcel Leist; Nick Tomczyk; John Rontree; James Langridge; Karin Danzer; Thomas Ciossek; Alina Petre; Michael L Gross; Bastian Hengerer; Michael Przybylski
Journal:  Chembiochem       Date:  2011-11-07       Impact factor: 3.164

3.  ATP13A2/PARK9 regulates secretion of exosomes and α-synuclein.

Authors:  Taiji Tsunemi; Kana Hamada; Dimitri Krainc
Journal:  J Neurosci       Date:  2014-11-12       Impact factor: 6.167

Review 4.  A predictable worm: application of Caenorhabditis elegans for mechanistic investigation of movement disorders.

Authors:  Paige M Dexter; Kim A Caldwell; Guy A Caldwell
Journal:  Neurotherapeutics       Date:  2012-04       Impact factor: 7.620

Review 5.  Movement disorders in 2011: Translating new research findings into clinical practice.

Authors:  Christine Klein; Dimitri Krainc
Journal:  Nat Rev Neurol       Date:  2011-12-20       Impact factor: 42.937

6.  GBA mutations increase risk for Lewy body disease with and without Alzheimer disease pathology.

Authors:  Debby Tsuang; James B Leverenz; Oscar L Lopez; Ronald L Hamilton; David A Bennett; Julie A Schneider; Aron S Buchman; Eric B Larson; Paul K Crane; Jeffrey A Kaye; Patricia Kramer; Randy Woltjer; Walter Kukull; Peter T Nelson; Gregory A Jicha; Janna H Neltner; Doug Galasko; Eliezer Masliah; John Q Trojanowski; Gerard D Schellenberg; Dora Yearout; Haley Huston; Allison Fritts-Penniman; Ignacio F Mata; Jia Y Wan; Karen L Edwards; Thomas J Montine; Cyrus P Zabetian
Journal:  Neurology       Date:  2012-10-03       Impact factor: 9.910

Review 7.  Immunotherapy for neurodegenerative diseases: focus on α-synucleinopathies.

Authors:  Elvira Valera; Eliezer Masliah
Journal:  Pharmacol Ther       Date:  2013-02-04       Impact factor: 12.310

Review 8.  The glycosphingolipid hydrolases in the central nervous system.

Authors:  Massimo Aureli; Maura Samarani; Nicoletta Loberto; Rosaria Bassi; Valentina Murdica; Simona Prioni; Alessandro Prinetti; Sandro Sonnino
Journal:  Mol Neurobiol       Date:  2013-11-27       Impact factor: 5.590

Review 9.  Autophagy in Parkinson's Disease.

Authors:  Xu Hou; Jens O Watzlawik; Fabienne C Fiesel; Wolfdieter Springer
Journal:  J Mol Biol       Date:  2020-02-13       Impact factor: 5.469

Review 10.  Dysregulation of the autophagic-lysosomal pathway in Gaucher and Parkinson's disease.

Authors:  Caleb Pitcairn; Willayat Yousuf Wani; Joseph R Mazzulli
Journal:  Neurobiol Dis       Date:  2018-03-14       Impact factor: 5.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.